Approval · Notice of Compliance 7617 · 2005
LIPITOR: Notice of Compliance 7617
Issued November 21, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7617
- Date
- November 21, 2005
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication for the reduction of the risk of myocardial infarction and stroke in adult patients with type 2 diabetes mellitus and hypertension without clinically evident coronary heart disease, but with other risk factors such as age greater than or equal to 55 years, retinopathy, albuminuria or smoking
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LIPITOR | Not yet assigned | — |
Medicinal ingredients
- ATORVASTATIN CALCIUM 10 MG per TAB
- ATORVASTATIN CALCIUM 20 MG per TAB
- ATORVASTATIN CALCIUM 40 MG per TAB
- ATORVASTATIN CALCIUM 80 MG per TAB